1
|
Kelly EM, Egan MJ, Colόn A, Angel SM, Sharma SK. Single-Grating Monolithic Spatial Heterodyne Raman Spectrometer: An Investigation on the Effects of Detector Selection. Appl Spectrosc 2023; 77:1411-1423. [PMID: 37801484 DOI: 10.1177/00037028231204894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/08/2023]
Abstract
Spatial heterodyne Raman spectrometers (SHRSs) are modified forms of Michelson interferometers, except the mirrors in a Michelson interferometer are replaced with stationary diffraction gratings. This design removes the need for an entrance slit, as is the case in a dispersive spectrometer, and removes the need to scan the spectrum by using a moving mirror in a modern Michelson interferometer. In previous studies, various SHRS variants, such as free-standing two-grating SHRS, single-grating SHRS (1g-SHRS), monolithic SHRS (mSHRS), and single-grating mSHRS (1g-mSHRS), have been evaluated. However, the present study exclusively focuses on the 1g-mSHRS configuration. The 1g-mSHRS and 1g-SHRS increase the spectral range at fixed grating line density while trading off spectral resolution and resolving power. The mSHRS benefits from increased rigidity, lack of moving parts, and reduced footprint. In this study, we investigate how the choice of detector impacts the performance of the 1g-mSHRS system, with a specific focus on evaluating the performance of three types of cameras: charged-coupled device (CCD), intensified CCD (ICCD), and complementary metal-oxide-semiconductor (CMOS) cameras. These systems were evaluated using geological, organic, and inorganic samples using a 532 nm continuous wave laser for the CMOS and CCD cameras, and a 532 nm neodymium-doped yttrium aluminum garnet pulsed laser for the ICCD camera. The footprint of the 1g-mSHRS was 3.5 × 3.5 × 2.5 cm3 with a mass of 272 g or 80 g, depending on whether the monolith housing is included or not. We found that increasing the number of pixels utilized along the x-axis of the camera increases fringe visibility (FV) and optimizes the resolution (by capturing the entirety of the grating and magnifying the fringes). The number of pixels utilized in the y-axis, chip size, and dimensions, affect the signal-to-noise ratio of the systems. Additionally, we discuss the effect of pixel pitch on the recovery of Fizeau fringes, including the relationship between the Nyquist frequency, aliasing, and FV.
Collapse
Affiliation(s)
- Evan M Kelly
- Hawaii Institute of Geophysics and Planetology, University of Hawaii at Manoa, Honolulu, Hawaii, USA
| | - Miles J Egan
- Hawaii Institute of Geophysics and Planetology, University of Hawaii at Manoa, Honolulu, Hawaii, USA
| | - Arelis Colόn
- Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina, USA
| | - S Michael Angel
- Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina, USA
| | - Shiv K Sharma
- Hawaii Institute of Geophysics and Planetology, University of Hawaii at Manoa, Honolulu, Hawaii, USA
| |
Collapse
|
2
|
Ricci JC, Hsi WC, Su Z, Mund K, Dawson R, Indelicato DJ. The root cause analysis on failed patient-specific measurements of pencil beam scanning protons using a 2D detection array with finite size ionization chambers. J Appl Clin Med Phys 2021; 22:175-190. [PMID: 34312997 PMCID: PMC8364270 DOI: 10.1002/acm2.13343] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 04/21/2021] [Accepted: 06/03/2021] [Indexed: 02/01/2023] Open
Abstract
The aim of this report is to present the root cause analysis on failed patient‐specific quality assurance (QA) measurements of pencil beam scanning (PBS) protons; referred to as PBS‐QA measurement. A criterion to fail a PBS‐QA measurement is having a <95% passing rate in a 3.0%‐3.0 mm gamma index analysis. Clinically, we use a two‐dimensional (2D) gamma index analysis to obtain the passing rate. The IBA MatriXX PT 2D detection array with finite size ionization chamber was utilized. A total of 2488 measurements performed in our PBS beamline were cataloged. The percentage of measurements for the sites of head/neck, breast, prostate, and other are 53.3%, 22.7%, 10.5%, and 13.5%, respectively. The measurements with a passing rate of 100 to >94%, 94 to >88%, and <88% were 93.6%, 5.6%, and 0.8%, respectively. The percentage of failed measurements with a <95% passing rate was 10.9%. After removed the user errors of either re‐measurement or re‐analysis, 8.1% became acceptable. We observed a feature of >3% per mm dose gradient with respect to depth on the failed measurements. We utilized a 2D/three‐dimensional (3D) gamma index analysis toolkit to investigate the effect of depth dose gradient. By utilizing this 3D toolkit, 43.1% of the failed measurements were improved. A feature among measurements that remained sub‐optimal after re‐analysis was a sharp >3% per mm lateral dose gradient that may not be well handled using the detector size of 5.0 mm in‐diameter. An analysis of the sampling of finite size detectors using one‐dimensional (1D) error function showed a large dose deviation at locations of low‐dose areas between two high‐dose plateaus. User error, large depth dose gradient, and the effect of detector size are identified as root causes. With the mitigation of the root causes, the goals of patient‐specific QA, specifically detecting actual deviation of beam delivery or identifying limitations of the dose calculation algorithm of the treatment planning system, can be directly related to failure of the PBS‐QA measurements.
Collapse
Affiliation(s)
- Jacob C Ricci
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.,Department of Radiation Oncology, University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA
| | - Wen C Hsi
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.,Department of Radiation Oncology, University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA
| | - Zhong Su
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.,Department of Radiation Oncology, University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA
| | - Karl Mund
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA
| | - Robert Dawson
- Department of Medical Physics, University of Florida College of Medicine, Gainesville, FL, USA.,Department of Radiation Oncology, Ackerman Cancer Center, Jacksonville, FL, USA
| | - Daniel J Indelicato
- Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.,Department of Radiation Oncology, University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA
| |
Collapse
|